Provided by Tiger Fintech (Singapore) Pte. Ltd.

IN8bio, Inc.

0.1471
-0.0056-3.67%
Post-market: 0.15080.0037+2.52%19:43 EDT
Volume:347.14K
Turnover:52.32K
Market Cap:11.95M
PE:-0.26
High:0.1562
Open:0.1517
Low:0.1449
Close:0.1527
Loading ...

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

GlobeNewswire
·
31 Mar

Mizuho Securities Sticks to Their Buy Rating for IN8bio (INAB)

TIPRANKS
·
20 Mar

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

GlobeNewswire
·
18 Mar

INAB: Introducing INB-600, A γδ T Cell Engager Platform

Zacks Small Cap Research
·
17 Mar

HC Wainwright Adjusts IN8bio Price Target to $6 From $8, Maintains Buy Rating

MT Newswires Live
·
14 Mar

IN8bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
14 Mar

IN8bio, Inc. : H.c. Wainwright Cuts Target Price to $6 From $8

THOMSON REUTERS
·
14 Mar

IN8bio Reports Progress in Cancer Therapies

TIPRANKS
·
14 Mar

IN8BIO Q4 Net Income USD -6.4 Million

Reuters
·
14 Mar

IN8bio: Maintaining Cash Position to Support Operations & Achievement of Anticipated Development Milestones Throughout 2025 & Into 2026

THOMSON REUTERS
·
14 Mar

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

GlobeNewswire
·
14 Mar

IN8bio announces gamma-delta T cell enager platform

TIPRANKS
·
03 Mar

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

GlobeNewswire
·
03 Mar

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

GlobeNewswire
·
24 Feb

INAB: Continued Survival in INB-100 Trial

Zacks Small Cap Research
·
19 Feb

IN8bio presented Phase 1 data on INB-100 at 2025 TCT

TIPRANKS
·
14 Feb

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

GlobeNewswire
·
14 Feb

Mizuho Securities Keeps Their Buy Rating on IN8bio (INAB)

TIPRANKS
·
12 Feb

BUZZ-IN8bio rises on early-stage data from cancer therapy

Reuters
·
12 Feb

Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), IN8bio (INAB)

TIPRANKS
·
12 Feb